Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Fertility and pregnancy issues in BRCA-mutated breast cancer patients.

Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, Del Mastro L, Demeestere I.

Cancer Treat Rev. 2017 Jul 14;59:61-70. doi: 10.1016/j.ctrv.2017.07.001. [Epub ahead of print] Review.

PMID:
28750297
2.

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart M, Ignatiadis M, Sotiriou C, Roger PP.

EMBO Mol Med. 2017 May 31. pii: e201607084. doi: 10.15252/emmm.201607084. [Epub ahead of print]

3.

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.

Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Review.

PMID:
28525810
4.

New agents for endocrine resistance in breast cancer.

Maurer C, Martel S, Zardavas D, Ignatiadis M.

Breast. 2017 Aug;34:1-11. doi: 10.1016/j.breast.2017.04.007. Epub 2017 Apr 24. Review.

PMID:
28448864
5.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C.

JAMA Oncol. 2016 Sep 29. doi: 10.1001/jamaoncol.2016.3824. [Epub ahead of print]

PMID:
27684533
6.

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A.

PLoS One. 2016 Jul 25;11(7):e0154009. doi: 10.1371/journal.pone.0154009. eCollection 2016.

7.

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga JY.

Eur J Cancer. 2016 Aug;63:97-104. doi: 10.1016/j.ejca.2016.04.024. Epub 2016 Jun 10. Review.

PMID:
27289552
8.

The current use and attitudes towards tumor genome sequencing in breast cancer.

Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart MJ, Sotiriou C, Ignatiadis M, Azim HA Jr.

Sci Rep. 2016 Mar 2;6:22517. doi: 10.1038/srep22517.

9.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
10.

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.

Ignatiadis M, Lee M, Jeffrey SS.

Clin Cancer Res. 2015 Nov 1;21(21):4786-800. doi: 10.1158/1078-0432.CCR-14-1190. Review.

11.

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?

Gingras I, Desmedt C, Ignatiadis M, Sotiriou C.

Clin Cancer Res. 2015 Nov 1;21(21):4743-6. doi: 10.1158/1078-0432.CCR-14-3127. Review.

12.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C.

Oncotarget. 2015 Oct 6;6(30):30306-16. doi: 10.18632/oncotarget.5080.

13.

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C.

Clin Adv Hematol Oncol. 2015 Jun;13(6):372-82. Review.

PMID:
26352893
14.

Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?

Gingras I, Salgado R, Ignatiadis M.

Curr Opin Oncol. 2015 Nov;27(6):560-7. doi: 10.1097/CCO.0000000000000223. Review.

PMID:
26335664
15.

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Drisis S, Metens T, Ignatiadis M, Stathopoulos K, Chao SL, Lemort M.

Eur Radiol. 2016 May;26(5):1474-84. doi: 10.1007/s00330-015-3948-0. Epub 2015 Aug 27.

PMID:
26310583
16.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C.

BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2.

17.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ.

Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.

18.

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists.

Ignatiadis M, Buyse M, Sotiriou C.

Ann Oncol. 2015 Aug;26(8):1519-20. doi: 10.1093/annonc/mdv259. Epub 2015 Jun 10. No abstract available.

PMID:
26063634
19.

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B.

BMC Genomics. 2014 Nov 21;15:1008. doi: 10.1186/1471-2164-15-1008.

20.

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

Ignatiadis M, Dawson SJ.

Ann Oncol. 2014 Dec;25(12):2304-13. doi: 10.1093/annonc/mdu480. Epub 2014 Oct 21. Review.

PMID:
25336116

Supplemental Content

Loading ...
Support Center